CHUNLI MEDICAL Surges Over 9% Intraday as HTSC Maintains "Buy" Rating

Deep News11-03

CHUNLI MEDICAL (01858) rose over 9% intraday, extending its post-earnings rally to nearly 25%. At the time of writing, the stock was up 7.87% to HK$20.42, with a turnover of HK$125 million.

The company recently reported strong financial results, with revenue for the first three quarters reaching RMB756 million, a 48.75% year-on-year increase. Net profit surged 213.21% to RMB192 million. In the third quarter alone, revenue grew 109.51% to RMB268 million, while net profit attributable to shareholders turned around to RMB77.06 million from a loss in the same period last year.

HTSC attributed the robust third-quarter performance to CHUNLI MEDICAL's steady expansion in international markets, continuous growth in export revenue, and increased sales of centralized procurement products. The brokerage remains optimistic about sustained rapid growth in overseas income and maintains its "Buy" rating on the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158341275?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 11:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158341275","market":"hk","top_or_hot":-1,"title":"CHUNLI MEDICAL Surges Over 9% Intraday as HTSC Maintains \"Buy\" Rating","media":"Deep News","content":"<p>CHUNLI MEDICAL (01858) rose over 9% intraday, extending its post-earnings rally to nearly 25%. At the time of writing, the stock was up 7.87% to HK$20.42, with a turnover of HK$125 million.</p>\n<p>The company recently reported strong financial results, with revenue for the first three quarters reaching RMB756 million, a 48.75% year-on-year increase. Net profit surged 213.21% to RMB192 million. In the third quarter alone, revenue grew 109.51% to RMB268 million, while net profit attributable to shareholders turned around to RMB77.06 million from a loss in the same period last year.</p>\n<p>HTSC attributed the robust third-quarter performance to CHUNLI MEDICAL's steady expansion in international markets, continuous growth in export revenue, and increased sales of centralized procurement products. The brokerage remains optimistic about sustained rapid growth in overseas income and maintains its \"Buy\" rating on the stock.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CHUNLI MEDICAL Surges Over 9% Intraday as HTSC Maintains \"Buy\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCHUNLI MEDICAL Surges Over 9% Intraday as HTSC Maintains \"Buy\" Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-11-03 11:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CHUNLI MEDICAL (01858) rose over 9% intraday, extending its post-earnings rally to nearly 25%. At the time of writing, the stock was up 7.87% to HK$20.42, with a turnover of HK$125 million.</p>\n<p>The company recently reported strong financial results, with revenue for the first three quarters reaching RMB756 million, a 48.75% year-on-year increase. Net profit surged 213.21% to RMB192 million. In the third quarter alone, revenue grew 109.51% to RMB268 million, while net profit attributable to shareholders turned around to RMB77.06 million from a loss in the same period last year.</p>\n<p>HTSC attributed the robust third-quarter performance to CHUNLI MEDICAL's steady expansion in international markets, continuous growth in export revenue, and increased sales of centralized procurement products. The brokerage remains optimistic about sustained rapid growth in overseas income and maintains its \"Buy\" rating on the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688236","symbol_name":"春立医疗","start_time":0,"source_url":"","article_id":"1158341275","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158341275","pubTimestamp":1762141292,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"CHUNLI MEDICAL (01858) rose over 9% intraday, extending its post-earnings rally to nearly 25%. At the time of writing, the stock was up 7.87% to HK$20.42, with a turnover of HK$125 million. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688236":"春立医疗","BK1147":"投资银行业与经纪业","BK1564":"中资券商股","BK1585":"昨日强势股","06886":"HTSC","BK0251":"专用设备","BK1100":"医疗保健设备","01858":"春立医疗"},"translate_title":"春立医疗盘中大涨超9%HTSC维持“买入”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688236":1,"06886":1,"01858":1},"content_text":"CHUNLI MEDICAL (01858) rose over 9% intraday, extending its post-earnings rally to nearly 25%. At the time of writing, the stock was up 7.87% to HK$20.42, with a turnover of HK$125 million.\nThe company recently reported strong financial results, with revenue for the first three quarters reaching RMB756 million, a 48.75% year-on-year increase. Net profit surged 213.21% to RMB192 million. In the third quarter alone, revenue grew 109.51% to RMB268 million, while net profit attributable to shareholders turned around to RMB77.06 million from a loss in the same period last year.\nHTSC attributed the robust third-quarter performance to CHUNLI MEDICAL's steady expansion in international markets, continuous growth in export revenue, and increased sales of centralized procurement products. The brokerage remains optimistic about sustained rapid growth in overseas income and maintains its \"Buy\" rating on the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158341275","isCrawlerRequest":true}